Table 2.
Crude and adjusted Cox regression analyses showing the effect modification of γ-Glutamyl-Transpeptidase on alkaline phosphatase for all-cause mortality. The criteria for building these models are detailed in the methods.
| Variables (units of increase) | Crude analysis | Fully adjusted analysis |
|---|---|---|
| Alk-Phos (50 UI/L) | 0.80 (0.67–0.96), P = 0.02 | 0.84 (0.69–1.02), P = 0.08 |
| GGT (quintiles) | 0.96 (0.84–1.09), P = 0.52 | 0.97 (0.85–1.12), P = 0.72 |
| Alk-Phos∗GGT (50 UI/L∗quintiles) | 1.08 (1.02–1.13), P = 0.004 | 1.06 (1.01–1.12), P = 0.02 |
| Age (1 year) | 1.05 (1.04–1.06), P < 0.001 | |
| Gender (0 = female; 1 = male) | 0.97 (0.77–1.21), P = 0.77 | |
| Current smoking (0 = no; 1 = yes) | 0.93 (0.67–1.29), P = 0.66 | |
| Diabetes (0 = no; 1 = yes) | 1.29 (1.03–1.62), P = 0.03 | |
| Systolic blood pressure (1 mmHg) | 1.00 (0.99–1.00), P = 0.67 | |
| CV comorbiditiesa (0 = no; 1 = yes) | 1.55 (1.24–1.94), P < 0.001 | |
| Antihypertensive treatment (0 = no; 1 = yes) | 1.12 (0.90–1.39), P = 0.98 | |
| Dialysis vintage (1 month) | 1.00 (1.00-1.00), P < 0.001 | |
| Cholesterol (1 mg/dL) | 1.00 (1.00-1.00), P = 0.002 | |
| Hb (1 g/dL) | 0.93 (0.86–0.99), P = 0.04 | |
| Phosphate (1 mg/dL) | 1.01 (0.94–1.08), P = 0.80 | |
| Albumin (1 g/dL) | 0.70 (0.55–0.88), P = 0.002 | |
| CRP (1 mg/L) | 1.00 (1.00-1.00), P = 0.56 | |
| Body Mass Index (BMI) (1 kg/m2) | 0.99 (0.97–1.02), P = 0.46 | |
| GOT (1 UI/L) | 1.01 (0.99–1.03), P = 0.45 | |
| GPT (1 UI/L) | 1.00 (0.99–1.01), P = 0.98 | |
| Bilirubin (1 mg/dL) | 0.91 (0.54–1.51), P = 0.70 | |
| HbsAg (0 = no; 1 = yes) | 0.73 (0.37–1.44), P = 0.37 | |
| HCV (0 = no; 1 = yes) | 0.81 (0.56–1.16), P = 0.25 | |
| Cirrhosis/hepatitis (0 = no; 1 = yes) | 1.26 (0.71–2.24), P = 0.44 | |
| Current alcohol consumption (0 = no; 1 = yes) | 1.12 (0.88–1.42), P = 0.34 |
Data are expressed as hazard ratio, 95% confidence interval (CI), and P values.
aCV comorbidities were defined as in Table 1.